Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
Brief Summary:
This study is being carried out to see if the drugs MEDI4736, Savolitinib and Tremelimumab can be used alone or in combination to reduce the size of tumours in patients with kidney cancer.
The drugs being tested in this study have an anti-tumour effect and have been tested in pre-clinical and human studies before. MEDI4736 and tremelimumab work with the immune system to help the body fight against tumour cells with immune cells. Savolitinib works to correct a faulty signal which causes tumour growth.
If a patient is eligible for the study and decides to take part, they will be enrolled into one of 3 stages of the study.